New test could tailor chemo for bile duct cancer patients after surgery
NCT ID NCT07156058
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing whether a quick lab test called MiniPDX can help doctors choose the best chemotherapy drugs for people with bile duct cancer after surgery. The test measures how sensitive a patient's tumor cells are to different drugs in just 7 days. Researchers will follow 204 participants to see if this personalized approach improves how long they stay cancer-free compared to standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- capecitabine, gemcitabine, cisplatin, oxaliplatin, 5-FU
- What this could lead to
- If successful, this could show that using a rapid drug sensitivity test helps choose more effective chemotherapy after surgery, potentially delaying cancer return.
- What could go wrong
- This is an early-stage, non-randomized study with no control group, so results may not prove the test improves outcomes. The test itself may not accurately predict drug response in all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- New drug cocktail aims to outperform standard immunotherapy in bile duct cancer
- Liver cancer registry aims to uncover new biomarkers from thousands of patients
- Triple-Drug cocktail targets Hard-to-Treat biliary cancers